• About us
• Contact

Advertisement

Organisation › Details

Millipore (Group)

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,100 employees in 47 countries worldwide. *

 

	Start	2003-11-01 existent
	Group	Merck (DE) (Group)
	Today	Merck Millipore Division (EMD Millipore Division)
	Successor	Merck Millipore Division (EMD Millipore Division)
	Industry	sample preparation (technology)
	Street	290 Concord Road
	City	01821 Billerica, MA
	Tel	+1-978-715-4321
		Address record changed: 2020-12-02
Basic data	Employees	G: 5,001 to 10,000 (2010-02-28)
	Currency	USD
	Annual sales	1,700,000,000 (sales (2009) 2009-12-31)
		* Document for »About Section«:
		Record changed: 2018-10-31

Advertisement

More documents for Merck (DE) (Group)

• [1] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
• [2] BioGeneration Ventures B.V.. (4/2/24). "Press Release: BGV Appoints Peter Halle, PhD as Venture Partner". Amsterdam....
• [3] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
• [4] Precirix N.V.. (2/29/24). "Press Release: Tom Plitz Commences Role as Chief Executive Officer of Precirix". Brussels....
• [5] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
• [6] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
• [7] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
• [8] Merck KGaA. (11/21/23). "Press Release: Merck Expands Newest Biologics Testing Center in Shanghai". Shanghai....
• [9] Merck KGaA. (11/14/23). "Press Release: Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District [Not intended for US-based media]". Darmstadt....
• [10] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.